Literature DB >> 1352027

Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants.

A D Levy1, L D Van de Kar.   

Abstract

Several classes of drugs that modify serotonin (5-HT) neurotransmission are either currently used, or are being evaluated for their potential use in the treatment of anxiety, schizophrenia, and depression. 5-HT1A agonists are considered potential anxiolytics, while some atypical antipsychotics are potent 5-HT2 antagonists (and also have modest dopamine D2 affinity). Furthermore, there is a diverse group of serotonergic drugs that may be effective antidepressants. Secretion of ACTH, corticosterone/cortisol, prolactin, renin, oxytocin and vasopressin are stimulated by activation of different 5-HT receptor subtypes, while other neurotransmitter receptors also influence the secretion of these hormones. We compared the receptor binding profiles of 5-HT anxiolytics, antipsychotics and antidepressants with their endocrine effects. These comparisons could aid in understanding both the therapeutic and side effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352027     DOI: 10.1016/0024-3205(92)90001-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Identification of metabolites produced from N-phenylpiperazine by Mycobacterium spp.

Authors:  M D Adjei; J Deck; T M Heinze; J P Freeman; A J Williams; J B Sutherland
Journal:  J Ind Microbiol Biotechnol       Date:  2006-12-22       Impact factor: 3.346

2.  Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man.

Authors:  H Y Meltzer; M Maes
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

3.  5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex.

Authors:  V A Vaidya; G J Marek; G K Aghajanian; R S Duman
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

4.  Single dose human pharmacology of umespirone.

Authors:  R L Holland; K Wesnes; B Dietrich
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates.

Authors:  S C Pandey; J M Davis; G N Pandey
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

6.  Investigation of the serum levels of anterior pituitary hormones in male children with autism.

Authors:  Keiko Iwata; Hideo Matsuzaki; Taishi Miyachi; Chie Shimmura; Shiro Suda; Kenji J Tsuchiya; Kaori Matsumoto; Katsuaki Suzuki; Yasuhide Iwata; Kazuhiko Nakamura; Masatsugu Tsujii; Toshirou Sugiyama; Kohji Sato; Norio Mori
Journal:  Mol Autism       Date:  2011-10-19       Impact factor: 7.509

7.  Anxiolytic and Antidepressant Effects of Maerua angolensis DC. Stem Bark Extract in Mice.

Authors:  Charles Kwaku Benneh; Robert Peter Biney; Donatus Wewura Adongo; Priscilla Kolibea Mante; Felix Agyei Ampadu; Augustine Tandoh; Jonathan Jato; Eric Woode
Journal:  Depress Res Treat       Date:  2018-09-09

8.  Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors.

Authors:  Betül Kaya; Leyla Yurttaş; Begüm Nurpelin Sağlik; Serkan Levent; Yusuf Özkay; Zafer Asim Kaplancikli
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.